perindopril has been researched along with Obesity in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 8 (33.33) | 24.3611 |
| 2020's | 4 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Batacan, R; Connolly, K; Fenning, A; Jackson, D; Vella, R | 1 |
| Ardiana, M; Harsoyo, PM; Hermawan, HO; Muhammad, AR; Sufiyah, IM; Suryawan, IGR; Zaini, BSI | 1 |
| Chalmers, J; Hamet, P; Harrap, S; Lee, AK; Marre, M; Mcevoy, JW; Ohkuma, T; Selvin, E; Sharrett, AR; Wang, D; Warren, B; Williams, B; Woodward, M | 1 |
| Brzozowska-Villatte, R; De Champvallins, M; Dézsi, CA; Farsang, C; Glezer, M; Karpov, Y | 1 |
| Chalmers, J; Coresh, J; Herrington, W; Li, Q; Mancia, G; Marre, M; Mohammedi, K; Perkovic, V; Poulter, N; Rodgers, A; Williams, B; Woodward, M | 1 |
| Chazova, IE; Elfimova, EM; Litvin, AY | 1 |
| Barykina, IN; Chumachok, EV; Ledyaeva, AA; Mazina, G; Nedogoda, SV; Salasyuk, AS; Tsoma, VV | 1 |
| Sharma, K; Sweiss, N | 1 |
| D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM | 1 |
| Cole, TJ; Morris, MJ; Smith, I; Velkoska, E; Warner, FJ | 1 |
| Batty, GD; Chalmers, J; Czernichow, S; Grobbee, DE; Huxley, R; Kengne, AP; Neal, B; Ninomiya, T; Woodward, M | 1 |
| Chumachok, EV; Lediaeva, AA; Mazina, GG; Nedogoda, SV; Salasiuk, AS; Tsoma, VV | 1 |
| Cao, G; DeRosa, G; Forcada, P; Pagano, P; Piorno, P; Rivas, C; Toblli, JE | 1 |
| Cao, G; DeRosa, G; Di Gennaro, F; Forcada, P; Toblli, JE | 1 |
| Belair, MF; Chainey, A; Chevalier, J; Mandet, C; Michel, O; Myara, I; Plante, GE; Renaud, IM | 1 |
| Cao, G; DeRosa, G; Forcada, P; Toblli, JE | 1 |
| Chowienczyk, PJ; Kearney, MT; Patel, AG; Shah, AM; Sherwood, RA; Wheatcroft, SB; Williams, IL | 1 |
| Bertrand, M; Daly, CA; Ferrari, R; Fox, KM; Hildebrandt, P; Remme, W; Simoons, M | 1 |
| Cao, G; Mastai, R; Mella, J; Muñoz, MC; Pereyra, L; Toblli, JE | 1 |
| Berrut, G; Fressinaud, P; Gallois, H | 1 |
| Bienz, R; Böhlen, L; Doser, M; Papiri, M; Riesen, W; Shaw, S; Weidmann, P | 1 |
| Abraham, AA; Michaelis, OE; Scalbert, E; Striffler, JS; Thibault, N; Velasquez, MT | 1 |
| Corradi, L; Fogari, R; Lazzari, P; Lusardi, P; Mugellini, A; Preti, P; Zoppi, A | 1 |
| Kuperstein, R; Sasson, Z | 1 |
3 review(s) available for perindopril and Obesity
| Article | Year |
|---|---|
Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypertension; Indapamide; Metabolic Syndrome; Middle Aged; Obesity; Perindopril; Treatment Outcome | 2021 |
Adiponectin effects on the kidney.
Topics: Adiponectin; Albuminuria; Amlodipine; AMP-Activated Protein Kinases; Animals; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Progression; Humans; Kidney; Kidney Diseases; Mice; Obesity; Oxidative Stress; Perindopril; Renal Insufficiency, Chronic; Telmisartan | 2014 |
[Antihypertensive action, clinical and biological acceptability of perindopril: main results in 23,460 patients with mild to moderate hypertension treated for 6 months in general practice].
Topics: Adult; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Diabetes Mellitus; Drug Evaluation; Drug Interactions; Female; Humans; Hypertension; Indoles; Male; Middle Aged; Obesity; Perindopril; Psychotropic Drugs; Risk Factors | 1993 |
11 trial(s) available for perindopril and Obesity
| Article | Year |
|---|---|
The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
Topics: Adult; Aged; Body-Weight Trajectory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations; Female; Follow-Up Studies; Gliclazide; Humans; Hypertension; Indapamide; Life Style; Male; Middle Aged; Obesity; Overweight; Perindopril; Risk Factors; Weight Gain; Weight Loss | 2020 |
Associations between body mass index and the risk of renal events in patients with type 2 diabetes.
Topics: Aged; Albuminuria; Blood Glucose; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Drug Combinations; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Indapamide; Kidney; Kidney Diseases; Male; Middle Aged; Obesity; Overweight; Perindopril; Reference Values; Renal Insufficiency | 2018 |
Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Enalapril; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Obesity; Overweight; Perindopril; Single-Blind Method; Telmisartan | 2013 |
Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Hypolipidemic Agents; Male; Nifedipine; Non-alcoholic Fatty Liver Disease; Obesity; Perindopril; Simvastatin | 2015 |
Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial.
Topics: Aged; Antihypertensive Agents; Body Weight; Cardiovascular Diseases; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Obesity; Overweight; Perindopril; Placebos; Proportional Hazards Models; Recurrence; Risk Reduction Behavior; Stroke | 2010 |
Divergent effects of angiotensin-converting enzyme inhibition on blood pressure and endothelial function in obese humans.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Brachial Artery; Endothelium, Vascular; Female; Humans; Lipid Metabolism; Male; Middle Aged; Obesity; Perindopril; Vasodilation | 2006 |
Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Body Mass Index; Coronary Artery Disease; Diabetes Mellitus; Europe; Female; Humans; Lipids; Male; Metabolic Syndrome; Middle Aged; Obesity; Perindopril; Prognosis; Risk Assessment | 2007 |
[Antihypertensive action, clinical and biological acceptability of perindopril: main results in 23,460 patients with mild to moderate hypertension treated for 6 months in general practice].
Topics: Adult; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Diabetes Mellitus; Drug Evaluation; Drug Interactions; Female; Humans; Hypertension; Indoles; Male; Middle Aged; Obesity; Perindopril; Psychotropic Drugs; Risk Factors | 1993 |
Metabolic neutrality of perindopril: focus on insulin sensitivity in overweight patients with essential hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Double-Blind Method; Exercise Test; Female; Humans; Hypertension; Indoles; Insulin; Lipids; Male; Middle Aged; Obesity; Perindopril | 1996 |
ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cross-Over Studies; Double-Blind Method; Female; Fibrinogen; Hemodynamics; Humans; Hypertension; Indoles; Insulin Resistance; Losartan; Male; Middle Aged; Obesity; Perindopril | 1998 |
Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives.
Topics: Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Glucose; Heart Ventricles; Humans; Hypertension; Insulin; Insulin Resistance; Male; Middle Aged; Myocardium; Obesity; Perindopril; Ventricular Function, Left | 2000 |
11 other study(ies) available for perindopril and Obesity
| Article | Year |
|---|---|
Perindopril prevents development of obesity and hypertension in middle aged diet-induced obese rat models of metabolic syndrome.
Topics: Animals; Blood Pressure; Diet, High-Fat; Hypertension; Male; Metabolic Syndrome; Obesity; Perindopril; Rats; Rats, Inbred WKY | 2023 |
Perindopril and losartan attenuate pro-coagulation factors in human adipocytes exposed to SARS-CoV-2 spike protein.
Topics: Adipocytes; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Blood Coagulation Factors; Cardiovascular Agents; COVID-19; Humans; Losartan; Male; Obesity; Perindopril; Plasminogen Activator Inhibitor 1; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Thromboplastin | 2023 |
The effectiveness of combination antihypertensive therapy in patients with arterial hypertension and additional risk factors: obesity and obstructive sleep apnea syndrome.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Combinations; Humans; Hypertension; Indapamide; Male; Obesity; Perindopril; Pulse Wave Analysis; Sleep Apnea, Obstructive | 2018 |
Metabolic effects of low dose angiotensin converting enzyme inhibitor in dietary obesity in the rat.
Topics: Adipose Tissue; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body Weight; Diet; Dietary Fats; Energy Intake; Energy Metabolism; Insulin; Leptin; Lipid Metabolism; Liver; Male; Obesity; Organ Size; Peptidyl-Dipeptidase A; Perindopril; Rats; Rats, Sprague-Dawley; Time Factors | 2010 |
[Efficiency perindopril at patients with arterial hypertension and obesity].
Topics: Adipose Tissue; Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Body Mass Index; Drug Monitoring; Enalapril; Female; Heart Function Tests; Humans; Hypertension; Insulin Resistance; Kidney Function Tests; Male; Metabolism; Middle Aged; Obesity; Perindopril; Protective Agents; Therapeutic Equivalency; Treatment Outcome | 2011 |
Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diuretics; Heart; Hypertension; Indapamide; Male; Myocardium; Obesity; Perindopril; Rats; Rats, Zucker; Ventricular Function, Left | 2003 |
Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Coronary Circulation; Disease Models, Animal; Immunohistochemistry; Male; Microvascular Angina; Myocardium; Neovascularization, Pathologic; Obesity; Organ Size; Perindopril; Rats; Rats, Zucker | 2004 |
Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Drug Combinations; Fibrosis; Indapamide; Kidney Function Tests; Male; Metabolic Clearance Rate; Obesity; Perindopril; Proteinuria; Rats; Rats, Zucker; Renal Insufficiency | 2004 |
Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor beta1 in obese Zucker rats by perindopril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Collagen; Disease Models, Animal; Male; Metabolic Syndrome; Myocardium; Obesity; Organ Size; Perindopril; Plasminogen Activator Inhibitor 1; Rats; Rats, Zucker; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Compounds; Disease Models, Animal; Fatty Liver; Interleukin-6; Irbesartan; Liver; Liver Cirrhosis; Male; Metabolic Syndrome; Obesity; Perindopril; Rats; Rats, Zucker; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2008 |
Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hydralazine; Hydrochlorothiazide; Hypertension; Indoles; Kidney Glomerulus; Kidney Tubules; Male; Obesity; Perindopril; Rats; Rats, Inbred SHR; Reserpine; Time Factors | 1997 |